Market Overview
The global metastases spinal tumor market is growing moderately, and it is expected to grow at the same pace over the forecast period 2017-2018. Increasing smoking and alcohol consumption is driving the growth of the market. Some other major factors such as changing healthcare practices, adoption of new therapies, and advancement in treatment facilities are also leading the market growth.
The global market of metastases spinal tumor was around USD 1241.5 million in 2016 and is expected to reach USD 1547.8 million by 2023 at a projected CAGR of 3.2%.
Early diagnosis can provide better treatment management of this disorder. Major diagnostic solution provider companies are engaged in developing and launching new medical imaging devices. Introduction and rapid adoption of advanced diagnostic devices are driving the market growth.
Segmental Analysis:
The global metastases spinal tumor market is segmented on the basis of type, which comprise extradural, metastatic spinal tumors of the bone, and others.
On the basis of diagnosis, this market is segmented into laboratory tests, imaging tests, biopsy, and others. Imaging tests includes X-Ray, Computed Tomography (CT scan), Magnetic Resonance Imaging (MRI scan), Angiography, F-18 fluorodeoxyglucose positron emission tomography, and others. Biopsy is sub-segmented into percutaneous needle biopsy, open incisional and excisional biopsy, and others.
On the basis of treatments, the market is segmented into non-operative treatment, surgical treatment, and others. Non operative treatment is sub-segmented into medications, radiation therapy, ablation, chemotherapy, and others. Medications includes anti-inflammatory drugs, narcotics (opioids), corticosteroids, rankl inhibitors and bisphosphonates, and others. Ablation is further sub-segmented into radiofrequency ablation, cryoablation, and others. Surgical treatment is further sub-segmented into minimally invasive surgery, open surgery, and others. Minimally invasive surgery is sub-segmented into vertebral fracture treatments, transarterial chemoembolization, and others. Vertebral fracture treatments is further sub-segmented into vertebroplasty, kyphoplasty (vertebral augmentation), and others. Open surgery includes spinal stabilization surgery, spinal decompression surgery, and others.
On the basis of end user, it is segmented into hospitals & clinics, ambulatory surgery centers, academic institutes, research centers, and others.
Competitive Analysis:
Some of the key players in this market: F. Hoffmann-La Roche Ltd (Switzerland), Amgen Inc. (US), Novartis AG(Switzerland), Abbott (US), Beckman Coulter Inc. (US), Debiopharm Group (Switzerland), AbbVie Inc. (US), Bayer AG (Germany), and others.
Brows Full detailed Report at https://www.marketresearchfuture.com/reports/metastases-spinal-tumor-market-4084
Regional Analysis:
The Americas dominate the global metastases spinal tumor market. An spinal tumor is a severe medical problem in Americas. North American countries such as the US and Canada dominate the market, while, Latin America region is also growing significantly. Due to highly advance medical facilities, focus on research and clinical trials, and upcoming healthcare bill, the US is expected to remain top revenue generating country in the global metastases spinal tumor treatment. Increasing number of patients with metastases spinal tumor is one of the major drivers for the Latin American market.
Europe is the second largest market for metastases spinal tumor treatment. This region is mainly divided into Eastern Europe and Western Europe.
And Many mOre
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
